Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...
MarketWatch24d
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...
The Motley Fool27d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.
Reuters24d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...